Day: June 17, 2020

Šiaulių Bankas AB, company code 112025254, address Tilžės str. 149, 76348 Šiauliai, Lithuania.As of June 15, Šiaulių Bankas has already postponed credit repayments to 626 customers who experienced financial difficulties caused by the COVID-19 pandemic and the announced quarantine. Business clients – 395 companies – account for the largest amount of loan deferrals, however, credit repayments were also temporarily suspended for 231 private customers.The bank’s customers, who have been facing financial challenges for three months, have been applying for deferral of credit repayments. According to Vytautas Sinius, the Chief Executive Office of Šiaulių Bankas, the bank provides assistance to the clients experiencing financial problems during this difficult period – from consultations to financial instruments.“We...

AB Šiaulių bankas, įmonės kodas 112025254, adresas Tilžės g. 149, 76348 Šiauliai, Lietuva.Birželio 15 d. duomenimis, Šiaulių bankas jau atidėjo kreditų mokėjimus 626 klientams, kurie patyrė finansinių sunkumų dėl COVID-19 viruso pandemijos ir paskelbto karantino. Daugiausiai paskolų atidėjimų sulaukė verslo klientai – 395 įmonės, kredito įmokų mokėjimai pristabdyti 231 privatiems klientams.Jau tris mėnesius su finansiniais iššūkiais susidūrę banko klientai teikia paraiškas kreditų įmokų atidėjimui. Pasak Šiaulių banko administracijos vadovo Vytauto Siniaus, šiuo sudėtingu laikotarpiu finansines problemas patiriantiems klientams bankas suteikia pagalbą – nuo konsultacijų iki finansinių instrumentų.„Su finansines problemas patiriančiais klientais aktyviai bendraujame ir pabandome ieškoti palankiausio sprendimo spręsti situaciją. Jei dėl...

MONTREAL, June 17, 2020 (GLOBE NEWSWIRE) — Kintavar Exploration Inc. (the “Corporation” or “Kintavar”) (TSX-V: KTR) (FRANKFURT: 58V), is pleased to announce the Sherlock corridor final winter drilling results and its comprehensive data compilation and analysis from the Mitchi project as it sets to begin its 2020 summer exploration program.“The Mitchi project is now entering the next stage in its exploration. With the main Sherlock zone well defined and the extensions better understood, our focus is to find and test additional mineralized zones from surface that could have volume potential ultimately leading to multiple open pit targets having minimal strip ratio potential similar to what we see at Sherlock.” commented Kiril Mugerman, President & CEO of Kintavar Exploration.“The Mitchi property does not lack exploration targets....

MONTRÉAL, 17 juin 2020 (GLOBE NEWSWIRE) — Exploration Kintavar Inc. (la « Société » ou « Kintavar ») (TSX-V: KTR) (FRANKFURT: 58V), a le plaisir d’annoncer les derniers résultats de forage du corridor Sherlock ainsi que la compilation et l’analyse complètes des données du projet Mitchi alors qu’elle débute son programme d’exploration estival 2020.« Le projet Mitchi entre maintenant dans la prochaine étape d’exploration. Avec la zone principale Sherlock bien définie et ses extensions mieux comprises, notre objectif est de trouver et d’investiguer de nouvelles zones minéralisées débutants en surface, qui auraient le potentiel d’avoir du volume, et qui pourraient ultimement devenir des cibles de fosses à ciel ouvert avec un coefficient de recouvrement minimal, similaire à celui observé sur Sherlock. » a commenté Kiril...

Lead product candidate ONS-5010 / LYTENAVATM (bevacizumab-vikg) has potential to be first FDA-approved ophthalmic formulation of bevacizumab for use in multiple retinal indications Topline results from NORSE 1, the Company’s first registration clinical trial evaluating ONS-5010 and providing clinical experience and initial safety and efficacy data, are expected in August 2020 NORSE 2 has enrolled 204 of 220 planned patients and is expected to complete enrollment no later than August 2020NORSE 3 open-label safety study designed to support planned BLA is expected to commence in Q4 2020MONMOUTH JUNCTION, N.J., June 17, 2020 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use...

NEW YORK, NY , June 17, 2020 (GLOBE NEWSWIRE) — Saratoga Investment Corp. (the “Company”) (NYSE: SAR) announced the commencement of a registered public offering of Notes due 2025 (the “Notes”).  The Company also announced that it has received an investment grade rating of “BBB” from Egan-Jones Ratings Company, an independent, unaffiliated rating agency.Egan-Jones is a Nationally Recognized Statistical Rating Organization (NRSRO) and is recognized by the National Association of Insurance Commissioners (NAIC) as a Credit Rating Provider (CRP). Egan-Jones is also certified by the European Securities and Markets Authority (ESMA).The Notes are expected to be listed on the New York Stock Exchange and to trade thereon within 30 days of the original issue date under the trading symbol “SAC”.Ladenburg Thalmann & Co. Inc., Janney Montgomery...

MONTREAL, June 17, 2020 (GLOBE NEWSWIRE) — WSP Global Inc. (TSX: WSP) (“WSP” or the “Corporation”) is pleased to announce that it has completed today its previously announced bought deal public offering (the “Offering”) of common shares (the “Common Shares”) of the Corporation (the “Offering Common Shares”) and private placement (the “Concurrent Private Placement”) of Common Shares (the “Placement Common Shares”) for aggregate gross proceeds of approximately $572 million.The Corporation issued from treasury 5,842,000 Offering Common Shares, including the 762,000 Offering Common Shares issued as a result of the full exercise of the over-allotment option granted to the syndicate of underwriters co-led by CIBC Capital Markets, National Bank Financial Inc. and TD Securities Inc. at a price of $86.00 per Offering Common Share, for aggregate...

MONTRÉAL, 17 juin 2020 (GLOBE NEWSWIRE) — Groupe WSP Global Inc. (TSX : WSP) (« WSP » ou la « Société ») est heureuse d’annoncer qu’elle a clôturé aujourd’hui son placement public par voie de prise ferme déjà annoncé (le « placement ») d’actions ordinaires (les « actions ordinaires ») de la Société (les « actions ordinaires placées dans le public ») et son placement (le « placement privé simultané ») d’actions ordinaires (les « actions ordinaires placées privément »), qui ont généré un produit brut total d’environ 572 millions de dollars.La Société a émis 5 842 000 nouvelles actions ordinaires placées dans le public, y compris 762 000 actions ordinaires placées dans le public qui ont été émises à l’exercice intégral de l’option de surallocation octroyée au syndicat de preneurs fermes codirigé par CIBC Marchés des capitaux, Financière...

Westport, CT, June 17, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced that it has commenced patient enrollment with the dosing of the first patient in its Phase II trial for merimepodib, a broad-spectrum, orally administered anti-viral drug candidate for the treatment of COVID-19 in adult patients. Confirmed trial sites include 3 sites from the Mayo Clinic including Rochester, MN, Jacksonville, FL, Phoenix, AZ and St. David’s South Austin Medical Center in Austin, TX and the Atlantic Health System -Overlook Hospital in Summit, NJ and Morristown Medical Center in Morristown, NJ.The Phase II trial is titled  “A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral Merimepodib...

NEW ALBANY, Ohio, June 17, 2020 (GLOBE NEWSWIRE) — Abercrombie & Fitch Co. (NYSE: ANF) (“A&F”) announced today that A&F’s indirect wholly-owned subsidiary, Abercrombie & Fitch Management Co. (“A&F Management”), plans to offer, subject to market and other customary conditions, up to $300 million aggregate principal amount of senior secured notes due 2025 (the “Senior Secured Notes”) in a private offering exempt from the registration requirements under the Securities Act of 1933, as amended (the “Securities Act”).The Senior Secured Notes will be guaranteed on a senior secured basis, jointly and severally, by A&F and each of the existing and future wholly-owned domestic restricted subsidiaries of A&F that guarantee or will guarantee A&F Management’s existing senior secured asset-based revolving...